about
Single vs. combination immunotherapeutic strategies for glioma.Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic dietA Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed GlioblastomaIsocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.MicroRNA and extracellular vesicles in glioblastoma: small but powerful.Advances in the molecular genetics of gliomas - implications for classification and therapy.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.The development of dendritic cell vaccine-based immunotherapies for glioblastoma.Angiogenesis inhibitors in tackling recurrent glioblastoma.T11TS repress gliomagenic apoptosis of bone marrow hematopoietic stem cells.The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.Engineering challenges for brain tumor immunotherapy.EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma PatientsGlioblastoma progression is assisted by induction of immunosuppressive function of pericytes through interaction with tumor cells.Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities.Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma.Current state and future prospects of immunotherapy for glioma.T-Cell Dysfunction in Glioblastoma: Applying a New Framework.Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity
P2860
Q33746041-AD927E2F-0D45-4577-96D1-CF8F0B859C06Q36017728-98C6DA7D-C1AE-4326-9684-EC2B44912805Q37262109-5CDE1BF2-0881-4F87-AD60-BDC34E6E939EQ37730613-01317503-6967-455D-80DD-6EC87BDAEECEQ38770220-5312A7D0-2AA7-4D1E-B3A1-B23AC24B80DCQ38777058-AA1B74A9-C2BE-449A-B6F2-94262F053BAEQ38789860-4F0C852B-7113-4B19-A833-525DD96A9B28Q38811369-14594283-0A30-42EF-A623-3D22E8C44DCDQ38984857-5A55E032-2321-4390-8D77-2F53C1C0FC71Q38990679-22FDEDFB-6634-4A67-BACA-6AE30E44ED00Q39259089-47C8060A-2741-4FDC-9584-42EAB3E7FA98Q39262483-9A4AD13F-CFAB-4A81-A417-C88B1D71A62FQ39294814-272C0DB4-50FF-4FA2-AD4A-A281A20EC17FQ39381281-9718E880-F495-482A-B507-4B3B78AB9DE1Q40089704-4AFF71AF-71E5-4355-B403-04B723B06FD2Q41472948-F3856026-5C80-4032-B972-18FFF8F60A6FQ41903951-D0E3F0DC-8FBD-4BC6-8111-7C2E98909375Q42000189-DE261AFE-12C6-4350-BD1E-DF99E3A188F5Q42282790-EA681FDB-00C7-4339-AA35-A80BE3B7FF3CQ42973443-04EE5F74-CBB6-4FE3-8DE9-C7E8A1EEF754Q47100447-C877E6B4-AD48-4AEC-B4AD-11CEB607C45CQ47827127-15583041-C9BE-4571-9EBD-126AAEAFB598Q48425908-C85E1D90-CF1D-4376-A543-C1E6C602CF8EQ50109459-DCF47C37-8917-4AAE-BACA-90930273A8ADQ52625023-2CD2AFE4-F9B0-41BD-AA78-FB0343E565D0Q52681027-8596730A-EBE3-4021-A29E-8E2DBAC05BAFQ53819014-F773A5CB-06FF-4933-AE5D-FA6704F6315DQ55257766-CCA08ACE-11BB-442D-9DC3-4B3F966D0D98Q55456543-3875C834-8E61-496E-93F5-853BE159F04AQ57135138-AC19A86F-E834-4A83-B6C9-9E9191E7B776
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immunosuppressive mechanisms in glioblastoma.
@ast
Immunosuppressive mechanisms in glioblastoma.
@en
type
label
Immunosuppressive mechanisms in glioblastoma.
@ast
Immunosuppressive mechanisms in glioblastoma.
@en
prefLabel
Immunosuppressive mechanisms in glioblastoma.
@ast
Immunosuppressive mechanisms in glioblastoma.
@en
P2860
P356
P1433
P1476
Immunosuppressive mechanisms in glioblastoma.
@en
P2093
Amy B Heimberger
Edjah K Nduom
P2860
P304
vii9-vii14
P356
10.1093/NEUONC/NOV151
P478
17 Suppl 7
P577
2015-11-01T00:00:00Z